Rac­ing af­ter the lead­ers, Eli Lil­ly's mi­graine drug clears an­oth­er piv­otal study

A month af­ter se­cur­ing ap­proval for clus­ter headaches, Lil­ly’s $LLY mi­graine drug Em­gal­i­ty has scored in a late-stage tri­al as a pre­ven­tive treat­ment for chron­ic and episod­ic mi­graines in pa­tients who have failed more than two stan­dard-of-care pro­phy­lac­tic treat­ments.

Em­gal­i­ty was the last in­jectable to win ap­proval for mi­graine pre­ven­tion last Sep­tem­ber, months af­ter Aimovig from Am­gen $AMGN  and No­var­tis $NVS, and Te­va’s $TE­VA Ajovy. Each has demon­strat­ed a re­duc­tion in mi­graine fre­quen­cy in about half of pa­tients when test­ed in clin­i­cal stud­ies and is priced at $6,900 a year, or $575 per month. Tiny Alder’s $AL­DR CGRP drug is un­der FDA re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER